CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH The Role of SATB1 in Breast Cancer Pathogenesis Researchers explored the potential of the SATB1 protein as a therapeutic target and prognostic marker for human breast cancer. [J Natl Cancer Inst] ARRDC3 Suppresses Breast Cancer Progression by Negatively Regulating Integrin Beta4 In this study, reserachers examined the cellular effects and molecular mechanism of the arrestin family member, ARRDC3, a gene preferentially lost in a subset of breast cancers. [Oncogene] The BH3-Only Protein Bad Confers Breast Cancer Taxane Sensitivity Through a Nonapoptotic Mechanism In this paper, researchers report that the proapoptotic BH3-only protein Bad has a major role in taxane-induced cell death in vitro, and clinically is a prognostic indicator for overall survival of breast cancer patients after adjuvant taxane chemotherapy. [Oncogene] BRCA2 Carriers”>Risk of Breast Cancer in Male BRCA2 Carriers The risk of breast cancer for unaffected men who test positive for a BRCA2 mutation is based on very few retrospective studies. Researchers have used both retrospective and prospective analysis in 321 families with pathogenic BRCA2 mutations. [J Med Genet] Kif18A is Inolved in Human Breast Carcinogenesis In this study, researchers report that Kif18A is overexpressed in human breast cancers and Kif18A overexpression is associated with tumor grade, metastasis and poor survival. [Carcinogenesis] Coclustering of ErbB1 and ErbB2 Revealed by FRET-Sensitized Acceptor Bleaching Here, researchers report the development of the fluorescence resonance energy transfer (FRET)-sensitized acceptor bleaching technique to quantitate the ratio of ErbB1 and ErbB2 in their heteroclusters. [Biophys J] Mammosphere-Forming Cells from Breast Cancer Cell Lines as a Tool for the Identification of CSC-Like- and Early Progenitor-Targeting Drugs Here, researchers show that a subpopulation of MCF-7 breast cancer cells which stains pale to Toluidine Blue, is endowed with features of cancer stem cells. [Cell Cycle] CLINICAL RESEARCH Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients While studies have found that adjuvant hormonal therapy for hormone-sensitive breast cancer (BC) dramatically reduces recurrence and mortality, adherence to medications is suboptimal. Researchers investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system. [J Clin Oncol]
|
|
INDUSTRY NEWS UC San Diego Researcher Awarded $5.3 Million for Breast Cancer Survivorship Study The University of California, San Diego School of Medicine has received a $5.3 million grant from the National Cancer Institute to conduct and lead a first-of-its-kind, four-year clinical trial to show the effects of weight loss and increased physical activity on quality of life and on co-existing medical conditions in overweight breast cancer survivors. [The University of California, San Diego School of Medicine Press Release] Calistoga Pharmaceuticals Raises $40 Million in Series C Financing Calistoga Pharmaceuticals, Inc. announced it has closed a $40 million Series C financing. The funds will be used to advance Calistoga Pharmaceuticals’ drug development pipeline of isoform-selective phosphatidylinositol 3 kinase inhibitors. [Calistoga Pharmaceuticals Press Release] Celgene to Acquire Abraxis BioScience Inc. Celgene Corporation and Abraxis BioScience Inc. jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. [Celgene Corporation Press Release]
|
|
POLICY NEWS Research Budgets Face Austerity in 2012 The National Institutes of Health and other life sciences and biomedical research funding agencies will need to trim their budgets for 2012, which are to be planned over the summer, to satisfy a White House that is now stressing deficit reduction and belt-tightening after two years of stimulus funding-boosted research budgets. [The Office of Management and Budget, United States] The Reality of Human Stem Cell Research in Europe A new report from the European Science Foundation examines the key scientific questions for human stem cell research in the context of the rapidly emerging field of regenerative medicine. [European Science Foundation, European Union] AstraZeneca Loses Generic Drug Case versus EU A European Union (EU) court backed an EU antitrust decision against Anglo-Swedish drug maker AstraZeneca, lending weight to a regulatory crackdown on firms blocking cheaper drugs coming to market. [The General Court, European Union] Strong Medicine for French Research The medical-research adviser to France’s president aims to shift power and money to universities. [National Research Agency, France] Meeting of the National Advisory Council for Healthcare Research and Quality [Agency for Healthcare Research and Quality, United States] Maryland Stem Cell Research Commission – Public Meeting Notice [Maryland Stem Cell Research Commission, United States] Center for Scientific Review; Notice of Closed Meetings [National Institutes of Health, United States] Science Board Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States] Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics [Food and Drug Administration, United States] Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications [Docket Nos. FDA-2010-M-0068, FDA-2010-M-0078, FDA-2010-M-0063, FDA-2010-M-0135, FDA-2010-M-0158] [Food and Drug Administration, United States]
|
|
EVENTS United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference July 12-14, 2010 Nottingham, United Kingdom 2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2) August 2-4, 2010 Singapore City, Singapore Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States 15th Congress of the European Society of Surgical Oncology (ESSO) September 15-17, 2010 Bordeaux, France 2010 World Cancer Congress August 18-21, 2010 Shenzhen, China 2010 Breast Cancer Symposium October 1-3, 2010 Washington, DC, United States 35th European Society for Medical Oncology (ESMO) Congress October 8-12, 2010 Milan, Italy International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy October 18-19, 2010 West Lafayette, United States 16th World Congress of the International Society of Senology October 20-22, 2010 Valencia, Spain The 2010 American Institute for Cancer Research (AICR) Annual Research Conference on Food, Nutrition, Physical Activity & Cancer October 21-22, 2010 Washington, DC, United States 6th National Cancer Research Institute (NCRI) Conference November 7-10, 2010 Liverpool, United Kingdom JOB OPPORTUNITIES Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies) Business Development Manager Europe – Cell Therapy Products (Pall Corporation) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities. Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
Have we missed an important article or publication in Mammary Cell News? Click here to submit! |
| |
|